OCV Partners
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at OCV Partners.
Key people at OCV Partners.
Key people at OCV Partners.
OCV Partners is a Los Angeles-based venture capital firm founded in 2016 that specializes in mid-to-late stage investments in technology and healthcare companies with differentiated technologies and compelling market positions.[1][6] The firm operates with a hands-on investment philosophy, leveraging decades of company-building experience from its founding partners to identify and create asymmetric advantages for the entrepreneurs it backs.[2] OCV's investment thesis centers on companies demonstrating strong revenue traction or regulatory progress that fall outside the comfort zones of traditional venture capital, typically deploying capital in the $10 million to $40 million range.[1]
The firm's core focus sectors are Technology (SaaS, FinTech, and PropTech) and Healthcare (Healthcare SaaS, Digital Health, MedTech, and BioTech).[2] OCV positions itself as a flexible capital partner with deep operational expertise, willing to lead funding rounds but not requiring it as a condition of investment.[2] The firm has demonstrated meaningful impact on the startup ecosystem through its portfolio of 20 investments and 4 portfolio exits, with recent investments including Rad AI (Series C, $60M) and OSSIO (Series C-II, $27.6M).[4]
OCV Partners was established in 2016 by a team of former founders and industry veterans, including co-founder and chairman Richard Ressler, alongside partners Andy Liu, Chris Bostick, and Hemi Zucker (Managing Partner).[6] The founding team's background as successful entrepreneurs who have grown businesses from early stages through IPOs and beyond directly shaped the firm's investment approach.[2] Rather than adopting a traditional venture capital model, the founders deliberately created a firm designed to back companies that needed operational and financial support but didn't fit neatly into conventional VC or private equity frameworks.
The firm closed its first fund in September 2017, establishing a $260.8 million investment management vehicle.[3][6] This founding structure reflected the partners' conviction that experienced operators could add significant value to mid-to-late stage companies navigating scaling challenges, market transformation, and operational complexity.
OCV's partners bring authentic company-building credentials rather than purely financial backgrounds. This translates into practical operational support beyond capital deployment—the firm has grown and acquired over 165 unique software companies, providing pattern recognition and playbooks that directly benefit portfolio companies.[2]
Unlike traditional VCs with rigid check-size requirements or lead/follow preferences, OCV operates with capital flexibility. The firm is comfortable following other investors or leading rounds, adapting its role to what serves the company's needs rather than institutional constraints.[2]
The firm maintains concentrated expertise in technology and healthcare rather than pursuing broad diversification. This focus enables the partners to leverage expansive networks of industry experts and entrepreneurs, creating meaningful introductions and partnerships for portfolio companies before and after funding.[2]
OCV deliberately targets companies with proven traction—$10+ million in revenue for technology companies or regulatory validation for life sciences firms.[1] This positioning allows the firm to de-risk investments while still capturing significant upside, avoiding the binary outcomes common in early-stage venture.
The firm's track record emphasizes building sustainable businesses through innovation, operational efficiency, and sound management rather than pursuing growth-at-all-costs strategies.[1] Portfolio company testimonials highlight OCV's ability to make strategic introductions and invest in founders as people, not just metrics.
OCV Partners operates at an inflection point in venture capital where the traditional early-stage/late-stage dichotomy is fragmenting. The firm captures a meaningful gap: companies that have achieved product-market fit and revenue traction but still need operational scaffolding and patient capital to navigate scaling challenges. This positioning reflects broader market trends including the maturation of SaaS, the acceleration of healthcare technology adoption, and the increasing complexity of regulatory environments in life sciences.
The firm's emphasis on healthcare and technology aligns with secular tailwinds reshaping capital allocation. Digital health, precision medicine, and enterprise software continue attracting institutional capital, but OCV's willingness to back companies outside traditional VC comfort zones—including those with complex regulatory pathways or non-traditional business models—positions it as a counterweight to herd-like venture capital behavior.
By backing companies that transform industries rather than simply disrupting them, OCV influences the broader ecosystem toward sustainable, operationally sound business building. The firm's portfolio exits and strategic board placements (such as Principal Zohar Loshitzer joining OSSIO's board) demonstrate active stewardship that extends beyond passive capital provision.[4]
OCV Partners represents a maturing segment of venture capital: the operator-led, sector-focused, mid-stage specialist. As venture capital continues fragmenting into specialized niches, firms like OCV that combine deep domain expertise with patient capital and operational support will likely see increasing relevance. The firm's track record in healthcare and technology—two sectors experiencing sustained institutional investment—positions it well for continued deal flow and portfolio appreciation.
The trajectory suggests OCV will deepen its specialization rather than broaden it. Future growth likely involves expanding its network effects within healthcare and technology ecosystems, potentially raising larger follow-on funds as the firm's track record compounds. The firm's ability to create asymmetric advantages through operational support and strategic introductions—rather than purely financial engineering—aligns with a broader market shift toward value-add venture capital in an era of capital abundance but operational scarcity.
For founders in healthcare and enterprise technology seeking capital partners who understand the operational complexity of scaling, OCV represents a compelling alternative to traditional venture capital, combining patient capital with authentic company-building expertise.